Economic feasibility of ‘Pay One Price’: an analysis of three biosimilar molecules with different prices and indicated for rheumatoid arthritis in a medium size HMO
Introduction/Objective: To evaluate the economic feasibility of a uniform ‘Pay One Price’ (POP) pricing model for three tumour necrosis factor (TNF) inhibitor biosimilars (adalimumab, infliximab, etanercept) used in rheumatoid arthritis (RA) treatment within a Brazilian medium-sized health maintenance organization (HMO). Methods: Medication prices were obtained from Brazil’s Chamber for the Regulation of the Medicines Market (CMED). […]
